Neuroablation for Chronic Foot Pain
Customize your policy alerts
Sign up for AmeriHealth Caritas Policy CCP.1370 alerts
Get alerted when Policy CCP.1370 changes without checking for updates manually.
Monitor payer policy activity
Governs coverage determinations for thermal or chemical neuroablation procedures intended to treat chronic foot pain (e.g., Morton's neuroma, plantar fasciitis, Achilles tendinosis); describes the payer's stance on medical necessity and alternative covered services.
No material clinical or coverage changes in this revision.
Coverage Determination
Not medically necessary
Covered when ALL of the following are met:
Applies to indications including Morton's neuroma, plantar fasciitis, Achilles tendinosis per policy.
Thermal ablation and chemoablation procedures for chronic foot pain are excluded from coverage because they are considered investigational and therefore not medically necessary. This policy stance applies to neuroablative interventions intended to treat chronic foot pain, including procedures targeting conditions such as Morton's neuroma, plantar fasciitis, and Achilles tendinosis.
Neuroablation (thermal or chemical) for chronic foot pain is considered investigational and not medically necessary. Professional guidance and evidence reviews are conflicting, and current recommendations do not support neuroablation as a primary treatment option for any etiology of chronic foot pain.
Specifically for Morton's neuroma (intermetatarsal nerve entrapment), available reports suggest chemical nerve ablation and radiofrequency ablation may improve symptoms in some patients, but the data are considered inconclusive and do not establish sufficient effectiveness to justify coverage.
Related Codes and Examples
Provider Requirements and Billing
Prior authorization not supported for investigational neuroablation
Neuroablation procedures for chronic foot pain are considered investigational and not medically necessary; prior authorization is not supported for thermal or chemoablation for chronic foot pain. Example procedure codes associated with these services include CPT 64632 and 0441T — submitters should not expect prior authorization approval under this policy.
Expect conservative therapies before invasive/experimental procedures
Providers are expected to follow standard conservative treatment algorithms — such as analgesic medications, physical therapy, orthoses, changes in footwear, off‑loading, corticosteroid injections, and surgery as indicated — before considering neuroablative procedures.
- Standard of care options listed: analgesia medications, physical therapy, orthoses, surgery.
- Conservative therapies described: anti‑inflammatory medications, off‑loading, footwear changes, orthoses, self‑care, corticosteroid injections, and physical therapy.
Include specific procedure codes and supporting clinical documentation
If submitting services related to neuroablative procedures, include the appropriate procedure code(s) (examples: 64632, 0441T) and clinical documentation that supports medical necessity and prior conservative treatments.
High denial risk for neuroablation services
Claims for thermal ablation or chemoablation to treat chronic foot pain risk denial because these interventions are considered investigational and not medically necessary under this policy.
- Policy statement: investigational/not clinically proven → not medically necessary; claims for these procedures may be denied.
Clinical Background
Foot pain arises from diverse neurogenic and musculoskeletal causes; identification of the anatomic location (forefoot, midfoot, hindfoot) helps guide diagnosis and management. Initial treatment typically emphasizes conservative measures — such as analgesics, activity modification, physical therapy, orthoses, and corticosteroid injections — with escalation to injections or surgery when those approaches fail. Neuroablation (including radiofrequency, cryoablation, or chemical techniques) aims to interrupt pain signaling by destroying or interrupting neural tissue, but the evidence base is limited, long-term benefit is uncertain, and optimal patient selection remains unclear.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.